SCHEMBL6338596

SCHEMBL6338596

CN(CCC(=O)c1ccccc1)Cc1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.77
SMN1; SMN2 Q16637 1/20 0.59
THRA P10827 1/20 0.55
THRB P10828 1/20 0.55
CARM1 Q86X55 1/20 0.53
PRMT6 Q96LA8 1/20 0.53
PRMT8 Q9NR22 1/20 0.53
EGFR P00533 2/20 0.52
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
CASP3 P42574 1/20 0.51
SENP8 Q96LD8 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
SENP6 Q9GZR1 1/20 0.51
KDM4A O75164 2/20 0.50
KDM4C Q9H3R0 2/20 0.50
SIGMAR1 Q99720 2/20 0.50
MEN1 O00255 1/20 0.50
TMEM97 Q5BJF2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5181661 0.98 KMT2A (0.74) KMT2ASMN1; SMN2THRATHRBCARM1
SCHEMBL11126800 0.97 KMT2A (0.77) KMT2ASMN1; SMN2THRATHRBCARM1
Hydrochloric Acid SCHEMBL11113894 0.95 KMT2A (0.75) KMT2ASMN1; SMN2THRATHRBCARM1
SCHEMBL13562531 0.91 KMT2A (0.63) KMT2ASMN1; SMN2THRATHRBCARM1
SCHEMBL4593680 0.90 KMT2A (0.62) KMT2ASMN1; SMN2NPC1RAB9ATDP1
SCHEMBL13562470 0.89 KMT2A (0.61) KMT2ASMN1; SMN2THRATHRBCARM1
SCHEMBL11982951 0.89 KDM4A (0.60) KMT2ASMN1; SMN2NPC1RAB9ATDP1
Hydrochloric Acid SCHEMBL4786199 0.88 TMEM97 (0.64) KMT2ASMN1; SMN2THRATHRBEGFR
SCHEMBL13562500 0.87 ACHE (0.68) KMT2AEGFRNPC1RAB9ATDP1
SCHEMBL13562515 0.87 KMT2A (0.58) KMT2ASMN1; SMN2THRATHRBEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0391070-B1 Process for the preparation of N-methyl-3-(p-trifluoro-methylphenoxy)-3-phenyl-propylamine and their salts ORION YHTYMAE OY (FI) 1994-01-19 EP claimed
US-5166437-A Process for the preparation of fluoxetine ORION-YHTYMA OY (FI) 1992-11-24 US claimed
US-20240287009-A1 AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME INFINEUM INTERNATIONAL LIMITED (GB) 2024-08-29 US disclosed
EP-4410772-A2 AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME Infineum International Limited (GB) 2024-08-07 EP disclosed
CN-118440229-A Amine functional monomers and methods of making the same 英菲诺姆国际有限公司 2024-08-06 CN disclosed
US-7709498-B2 Quinoline derivatives as antibacterial agents JANSSEN PHARMACEUTICA N.V. (BE) 2010-05-04 US disclosed
US-7709498-B2 Quinoline derivatives as antibacterial agents JANSSEN PHARMACEUTICA N.V. (BE) 2010-05-04 US disclosed
WO-2007009405-A1 A METHOD FOR THE PREPARATION OF (R)-N-METHYL-3-(2-METHYLPHENOXY)-3-PHENYLPROPYLAMINE HYDROCHLORIDE (ATOMOXETINE) ZENTIVA, A.S. (CZ) 2007-01-25 WO disclosed
US-6838581-B2 Process for the preparation of enantiomerically pure 3-phenyl-3-hydroxypropylamine COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2005-01-04 US disclosed
US-20040110985-A1 Process for the preparation of enantiomerically pure 3-phenyl-3-hydroxypropylamine COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2004-06-10 US disclosed
EP-0929514-A1 PROCESS FOR THE PREPARATION OF FLUOXETINE EGIS GYOGYSZERGYAR RT. (HU) 1999-07-21 EP disclosed
WO-1998011054-A1 PROCESS FOR THE PREPARATION OF FLUOXETINE EGIS Gyógyszergyár Rt. (HU) 1998-03-19 WO disclosed
EP-0391070-B1 Process for the preparation of N-methyl-3-(p-trifluoro-methylphenoxy)-3-phenyl-propylamine and their salts ORION YHTYMAE OY (FI) 1994-01-19 EP disclosed
EP-0391070-A1 Process for the preparation of N-methyl-3-(p-trifluoro-methylphenoxy)-3-phenyl-propylamine and their salts ORION-YHTYMÄ OY FERMION (FI) 1990-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110985-A1 Process for the preparation of enantiomerically pure 3-phenyl-3-hydroxypropylamine CYP2D6, ADH1A, TPH1 KMT2A 1175/4885SMN1; SMN2 2307/4885THRA 3943/4885
US-20240287009-A1 AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME AMD1, HNMT, MAT1A KMT2A 134/4885SMN1; SMN2 1268/4885THRA 2345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.